Plasma glial fibrillary acidic protein and neurological diseases: A bidirectional Mendelian randomization study
- 1 September 2025
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (2) , 806-818
Abstract
Background: Increased glial fibrillary acidic protein (GFAP) in blood, a biomarker of reactive astrogliosis and astrocytic injury, was observed in a variety of neurological disorders. However, the causal relationship between plasma GFAP and neurological disorders remains unclear. Objective: We aim to investigate causal association between plasma GFAP levels and neurological disorders using bidirectional Mendelian randomization (MR). Methods: The genome-wide association studies for neurological disorders, including neurodegenerative diseases, neuroimmune disorders, cerebrovascular diseases, and epilepsy, were collected. Genetic variables associated with plasma GFAP levels were obtained from the UK Biobank Pharma Proteomics Project. Inverse variance weighted or Wald ratio method was used as the main analysis to assess the causal association. Results: Genetically predicted higher plasma GFAP levels were found to be associated with an increased risk of encephalitis (odds ratio [OR] = 2.52; 95% confidence interval [CI] = 1.67–3.47; p = 1.22 × 10 –5 ). Furthermore, we found that Alzheimer's disease (β = 0.05; standard error [SE] = 0.01; p = 6.63 × 10 –8 ), frontotemporal dementia (β = 0.12; SE = 0.01; p = 5.10 × 10 –16 ), and dementia with Lewy bodies (β = 0.08; SE = 0.02; p = 5.45 × 10 –5 ) were causally linked to an increase in plasma GFAP levels. Even after controlling for the influence of aging, these associations remained significant. Conclusions: Our study found that higher plasma GFAP levels may increase the risk of encephalitis, while neurodegenerative dementia may enhance the plasma GFAP levels, supporting the clinical utility of blood GFAP as a reliable biomarker in neurological diseases.Keywords
Funding Information
- National Natural Science Foundation of China (82271464)
This publication has 61 references indexed in Scilit:
- C5aR1 signaling promotes region‐ and age‐dependent synaptic pruning in models of Alzheimer's diseaseAlzheimer's & Dementia, 2024
- Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research InitiativeAlzheimer's & Dementia, 2023
- Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progressionAlzheimer's & Dementia, 2023
- Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health studyAlzheimer's & Dementia, 2023
- Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body diseaseAnnals of Clinical and Translational Neurology, 2023
- Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognitionAlzheimer's & Dementia, 2022
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumJAMA Neurology, 2021
- Mendelian RandomizationJAMA, 2017
- Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infectionsJournal of Neurology, 2013
- Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destructionJournal of Neurology, 2000